Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05987332 · ClinicalTrials.gov registry record · Phase 2

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma, sponsored by IDEAYA Biosciences.

Active
Registry status
Phase 2
Development phase
420
Enrollment target
20
Study locations

NCT05987332 is a Phase 2 study of Metastatic Uveal Melanoma that is active but no longer recruiting, run by IDEAYA Biosciences. The registered enrollment target is 420 participants, above the 103-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (308% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05987332, a Phase 2 study of Metastatic Uveal Melanoma, is active but no longer recruiting, sponsored by IDEAYA Biosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
420 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG IDE196
  • DRUG Crizotinib

Study Locations (20)

California

  • Moores Cancer Center - La Jolla
  • UCLA Medical Center - Los Angeles
  • The Angeles Clinic and Research Institute - Los Angeles
  • California Pacific Medical Center (CPMC) - San Francisco
  • University of California San Francisco - San Francisco

Colorado

  • University of Colorado Cancer Center - Aurora
  • SCRI at HealthONE - Denver

Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Minnesota

  • Minnesota Oncology Hematology, P.A. - Burnsville
  • Mayo Clinic - Rochester

New York

  • Roswell Park Cancer Institute - Buffalo
  • Northwell Health - Manhasset

Arizona

  • Honor Health - Scottsdale

Georgia

  • Northside Hospital Atlanta - Atlanta

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2023-10-31
Est. Completion 2028-01-15
Phase Phase 2

Sponsor

IDEAYA Biosciences

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05987332

The ClinicalTrials.gov registry entry for NCT05987332 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (308% higher). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05987332 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT05987332 about?

NCT05987332 is a clinical study titled "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma". This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab...

What is the current status of trial NCT05987332?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2023-10-31. Estimated completion is 2028-01-15.

What conditions does trial NCT05987332 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT05987332?

The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), IDE196 (DRUG), Crizotinib (DRUG).

Who is sponsoring clinical trial NCT05987332?

This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05987332 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Uveal Melanoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.